Odense University Hospital

At Odense University Hospital, investigators are evaluating a novel immunotherapy combined with standard post‑surgical treatment for women with high‑risk disease. The purpose is to improve long‑term outcomes by reducing cancer recurrence.

• Disease‑free survival assessment
• Overall survival measurement
• Combination with adjuvant chemotherapy
• Optional radiotherapy integration
• Post‑surgical curative intent

The study seeks to determine whether adding the immune‑checkpoint inhibitor can extend both disease‑free and overall survival, offering a potential new standard of care for patients.

In a collaborative effort at Odense University Hospital, researchers are testing an inhaled therapy designed to target fibrotic pathways in the lungs. The trial focuses on safety and early signals of efficacy in a progressive lung condition.

• Inhaled MMP7 inhibitor evaluation
• Safety and tolerability monitoring
• Pulmonary function testing
• Biomarker profiling
• Quality‑of‑life assessment

By exploring a localized treatment approach, the research hopes to slow disease progression and improve breathing capacity for patients with this challenging condition.